- 2023 - 2028
Utility of Biomarkers of Rejection and Kidney Injury in Tailoring Liver Transplant Immunosuppression. National Institutes of Health (Sub-Investigator)
- 2023 - 2027
The Immunogenicity and Pathogenicity of HLA-DQ. National Institute of Allergy and Infectious Diseases (NIAID) - Principal Investigator.
- 2023 - 2024
Investigating HLA-DQ Immunogenicity: Site Directed Mutagenesis of Candidate Amino Acid Targets. Northwestern University - Comprehensive Transplant Center, The Dr. Michael M. Abecassis Transplant Innovation Endowment Grant
- 2022 - 2027
Comparison of High vs Standard Dose Influenza Vaccines in Lung Transplant Recipients. National Institute of Allergy and Infectious Diseases (NIAID) - Sub-Investigator (Halasa - Principal Investigator)
- 2022 - 2023
A Biomarker for Endothelial Health in Transplantation. Northwestern University - Comprehensive Transplant Center, The Dr. Michael M. Abecassis Transplant Innovation Endowment Grant (Co-Investigator)
- 2021 - 2022
Understanding the Immunogenicity of HLA-DQ Antibodies in Solid Organ Transplantation. Northwestern University - Comprehensive Transplant Center, The Dr. Michael M. Abecassis Transplant Innovation Endowment Grant
- 2020 - 2025
Comparison of High vs Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients. National Institute of Allergy and Infectious Diseases (NIAID) - Sub-Investigator (Halasa - Principal Investigator)
- 2020 - 2023
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuxumab in Patients Awaiting Kidney Transplantation. Sanofi-Adventis
- 2020 - 2021
CRISPR/Cas9 Edited Singly Expressed HLA Class II Cells for the Study of HLA-DQ Immunogenicity. Northwestern University -Comprehensive Transplant Center, The Dr. Michael M. Abecassis Transplant Innovation Endowment Grant
- 2020 - 2025
Analyzing the Immunogenicity of HLA-DQ in Solid Organ Transplantation. Vanguard Charitable Endowment - Paul I. Terasaki fund
- 2018 - 2021
HLA-DQ Immunogenicity and its Role in Antibody Mediated Rejection in Solid Organ Transplantation. Paul I. Terasaki Research Foundation
- 2018 - 2023
Paul I. Terasaki Research Grant for HLA Director in Training Fellowship
- 2016 - 2020
Astagraf XL to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation. Astellas Pharma Global Development, Inc
- 2008 - 2011
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial to Evaluate the Long-term Safety and Efficacy of CP-690,550 in Renal Allograft Recipient. A3921050-1046 (Investigator)
- 2008 - 2011
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor Stem Cell Infusion. University of Louisville (Sub-Investigator)
- 2007 - 2010
Randomized Conversion of Calcineurin Inhibitor (Tacrolimus to Sirolimus) at 6-24 Months Post Transplant in a Prednisone-free Immunosuppression Regimen: Impact on Acute Rejection, Renal Allograft Function, and T Cell Function. Wyeth (Investigator)
- 2007 - 2008
Immune Tolerance Profiles after Conversion from Tacrolimus to Sirolimus in Liver Transplant Recipients. Wyeth (Investigator)
- 2007 - 2012
Donor Stem Cells, Campath, T/B Cell Regulation in HLA-Identical Renal Transplants. National Institutes of Health (Investigator)
- 2006 - 2011
CTOT-02: B Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients who Develop De Novo Anti-HLA Alloantibodies will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection. National Institutes of Health (DAIT, NIAID) (Sub-Investigator)
- 2006 - 2008
Immunophenotyping and Functional Profiles of Peripheral Lymphocytes in Renal Transplant Recipients after T-Cell Depletion with Alemtuzumab (Anti-CD52 Monoclonal Antibody) - Potential Implications for Safe Immunosuppressive Minimization. American Society of Transplantation (Sub-Investigator)
- 2006 - 2007
Desensitization for Highly Sensitized Recipients of Pancreas Transplantation. NMF (Co-Investigator)
- 2005 - 2007
Immunological Response to Stem Cell Transplantation. CINN (Co-Investigator)
- 2005 - 2009
A Phase IV, Single Center Pilot Study using Alemtuzumab (Campath-1H) Induction Combined with Prednisone-free and Calcineurin Inhibitor-free Immunosuppression in Kidney Transplantation. Roche(Investigator)
- 2005 - 2008
Desensitization of Crossmatch Positive Renal Transplant Recipients using Alemtuzumab. Ilex Oncology, Inc. (Co-Investigator)
- 2004
Photopheresis Treatment - Its Effects on Immune Cells. Theracos, Inc (Principal Investigator)
- 1999 - 2001
Risk Stratification of Heart Transplant Recipients by Flow Cytometry Detected Antibodies against Histocompatibility Molecules. American Heart Association, Mid-west Affiliate; #9951446Z (Principal Investigator)
- 1998 - 1999
In-Vitro Protection of Human Lymphocytes and Neuronal Cells against Oxidation Damage by Ethoxyquine Phosphate and Propyl Gallate. Burlington Bio-Medical & Scientific Corporation (Principal Investigator)
- 1997 - 1998
The Role of Ultraviolet B Irradiation in Antigen Processing and Presentation. University Committee on Research, Rush Medical College
- 1997 - 1998
Construction of Pgp-Deficient Cells. American Cancer Society, New Investigator Grant
- 1989 - 1991
Immunogenetics of Primary Sjogren's Syndrome in Jewish Patients. Israel Ministry of Health, #1579